Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Implanet S.A. is a medical technology company specializing in the development, production, and marketing of high-quality implants for orthopedic surgery, with a focus on vertebral and knee pathologies. Founded in 2007 and headquartered in Bordeaux, France, Implanet has carved a niche in the spinal and orthopedic sectors through its innovative solutions, including the JAZZ® platform, a proprietary technology designed to address various spine deformities and surgical complexities. The company's products are essential for surgeons managing spinal conditions such as scoliosis and degenerative disc diseases. In addition to its operations in Europe, Implanet is expanding its market presence globally, including strategic partnerships and distribution agreements in North America and other key markets. By focusing on safety, reliability, and performance, Implanet plays a significant role in the broader medical device industry, contributing to advancements in surgical techniques and patient care. Implanet's commitment to innovation and quality in medical devices positions it as a vital player within the competitive landscape of orthopedic solutions.
The business is unprofitable at the operating level (-31.49% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 32.6% YoY with margins expanding 19.7pp.
Negative free cash flow of -€2M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€12M
▲ +32.6% YoY
Net Income (TTM)
-€4M
▼ -0.4% YoY
Op. Margin
-31.49%
▲ +19.7pp YoY
ROIC
-46.92%
▲ +11.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€2M
▲ +29.2% YoY
Op. Cash Flow (TTM)
-€984K
▲ +53.3% YoY
Net Debt
€3M
Cash & Equiv.
€3M
3Y CAGR: +15.8%
Continue Research